Alcohol use disorder in community management of chronic liver diseases
Hepatology · 2023
DOI: 10.1002/hep.32531 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology, 2023. Verfasst von Lorenzo Leggio und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section , Translational Addiction Medicine Branch , National Institute on Drug Abuse an…. Hauptthemen laut MEDLINE: Alcoholism, Liver Diseases, Alcoholic, Hepatitis, Alcoholic. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 128 Literaturangaben. Gefördert von: NIAAA NIH HHS, Intramural NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Rising rates of alcohol use disorder (AUD) combined with increases in alcohol‐related liver disease (ALD) and other liver disease have resulted in the need to develop alcohol management strategies at all levels of patient care. For those with pre‐existing liver disease, whether ALD or others, attention to alcohol use treatment and abstinence becomes critical to avoiding worsening liver‐related consequences. Modalities to help patients reduce or stop alcohol include screening/brief intervention/referral to treatment, various therapeutic modalities including cognitive behavioral therapy, motivational enhancement therapy and 12‐step facilitation, and alcohol relapse prevention medications. Harm reduction approaches versus total abstinence may be considered, but for those with existing ALD, particularly advanced ALD (cirrhosis or acute alcoholic hepatitis), total abstinence from alcohol is the recommendation, given clear data that ongoing alcohol use worsens mortality and liver‐related morbidity. For certain populations, alcohol cessation is even more critically important. For those with hepatitis C or NAFLD, alcohol use accelerates negative liver‐related outcomes. In women, alcohol use accelerates liver damage and results in worsened liver‐related mortality. Efforts to integrate AUD and liver disease care are urgently needed and can occur at several levels, with establishment of multidisciplinary ALD clinics for fully integrated co‐management as an important goal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section , Translational Addiction Medicine Branch , National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism , National Instit…
- Medication Development Program , National Institute on Drug Abuse Intramural Research Program , National Institutes of Health , Baltimore , Maryland , USA.
- Center for Alcohol and Addiction Studies , Department of Behavioral and Social Sciences , School of Public Health , Brown University , Providence , Rhode Island , USA.
- Division of Addiction Medicine , Department of Medicine , School of Medicine , Johns Hopkins University , Baltimore , Maryland , USA.
- Department of Neuroscience , Georgetown University Medical Center , Washington , DC , USA.
- Department of Internal Medicine , Michigan Medicine , Ann Arbor , Michigan , USA.
ORCID-Profile: Lorenzo Leggio, Jessica L Mellinger
Förderung
- NIAAA NIH HHS
- Intramural NIH HHS
Zitieren
APA
Leggio, L., & Mellinger, J. L. (2023). Alcohol use disorder in community management of chronic liver diseases. Hepatology. https://doi.org/10.1002/hep.32531
Vancouver
Leggio L, Mellinger JL. Alcohol use disorder in community management of chronic liver diseases. Hepatology. 2023. doi:10.1002/hep.32531
BibTeX
@article{Leggio2023,
author = {Leggio, Lorenzo and Mellinger, Jessica L},
title = {Alcohol use disorder in community management of chronic liver diseases},
journal = {Hepatology},
year = {2023},
doi = {10.1002/hep.32531}
}
EUVIMED